Chimeric Protein PSPF, a Potential Vaccine for Prevention Streptococcus pneumoniae Infection

Suvorov, Alexander; Духовлинов, И. В.

doi:10.4172/2157-7560.1000304

Cited by 4 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For citation: Suvorov AN**, Kramskaya TA, Gupalova TV, et [4][5][6][7][8][9][10][11]. https://doi: 10.31631/2073-3046-2023-22-4-4-11 В акцинная профилактика является одним из наиболее эффективных способов за щиты от инфекционных заболеваний и их распространения [1].…”

Section: Abstract: Mucosal Vaccines Recombinant Strains Probiotics E ...unclassified

“…Ключевым индикатором эффективного иммун ного ответа на вакцинацию служит высокий уро вень специфических иммуноглобулинов в крови [3][4][5]. Такой подход с некоторыми вариациями успешно используется при оценке вакцин во всех странах мира.…”

Section: Abstract: Mucosal Vaccines Recombinant Strains Probiotics E ...unclassified

See 1 more Smart Citation

Mucosal Vaccines against Bacterial and Viral Pathogens

Suvorov,

Kramskaya,

Gupalova

et al. 2023

Epidemiology and Vaccinal Prevention

View full text Add to dashboard Cite

The mucosal membranes of the human body play a crucial role in the development, maintenance, and regulation of barrier functions and immune homeostasis, representing an integral component of the overall immune system. Mucosal vaccines elicit immune processes in the lymphoid tissue associated with the mucosal membranes. A critical objective of mucosal immunization is the identification of an antigen delivery vector capable of ensuring optimal vaccine efficacy. The authors of this article have conducted extensive research on the probiotic properties of enterococci over an extended period. They employ a safe and beneficial probiotic strain, Enterococcus faecium L3, as a delivery vector for vaccine antigens. Initially, the gene encoding the pathogenicity factor Bac, derived from group B streptococci (Streptococcus agalactiae), was successfully integrated into the genome of the probiotic strain E. faecium L3. Intravaginal, oral, and intranasal mucosal immunization methods utilizing the L3-Bac+ probiotic, which expresses antigenic determinants of pathogenic streptococci, were found to confer protection against bacterial infection in laboratory animals. Subsequently, recombinant technologies were refined, leading to the development of a universal method for incorporating a region of interest from the gene into the structure of the major pili protein gene of E. faecium L3. Using this technology, candidate vaccines against various infections, including Streptococcus pneumoniae, influenza A virus, and SARS-CoV-2 following the onset of the Covid-19 pandemic, have been obtained and tested. In this study, alongside the presentation of our own data, the challenges associated with utilizing recombinant probiotic bacteria as vectors for vaccine antigen delivery are discussed.

show abstract

Section: Abstract: Mucosal Vaccines Recombinant Strains Probiotics E ...unclassified

Mucosal Vaccines against Bacterial and Viral Pathogens

Suvorov,

Kramskaya,

Gupalova

et al. 2023

Epidemiology and Vaccinal Prevention

View full text Add to dashboard Cite

show abstract

Recombinant vaccine candidates with integrated adjuvants provide stimulation of an effective immune response against bacterial infections

Leontieva

Kramskaya

Grabovskaya

et al. 2023

jour

View full text Add to dashboard Cite

The use of recombinant proteins as vaccine preparations is limited by their weak immunogenicity, which can be enhanced by the use of adjuvants, the development of which is an important and urgent problem of modern vaccinology. Significantly, adjuvants as additives to vaccine preparations are of concern to clinicians. From this point of view, the idea of including an internal adjuvant into the structure of a recombinant protein molecule is of undoubted interest. Previously, we synthesized and studied two recombinant vaccine preparations specific for S. agalactiae (Su4) and S. pneumoniae (PSPF). Each of them was a tandem of immunogenic bacterial surface proteins in combination with an additional adjuvant site. The amino acid sequence identical to flagellin acted as an internal adjuvant. In this work, we investigated the possibility of additional enhancement of the body’s immune response to immunization with recombinant Su4 and PSPF proteins due to the simultaneous administration of an external adjuvant, carboxymethylchitosan or Imject Alum.Studies have shown that the additional introduction of these adjuvants into the composition of the vaccine preparation did not affect the immunogenicity of the Su4 and PSPF proteins, which included the internal adjuvant flagellin. The protective efficacy of the immune response to all immunization options was comparable.Thus, the inclusion of a flagellin insert as an internal adjuvant into the composition of recombinant proteins ensures the development of the highest possible level of the immune response and its protective efficacy against the corresponding pathogens of a bacterial infection.

show abstract

Non-capsular based immunization approaches to prevent Streptococcus pneumoniae infection

Silva

Vázquez

Campusano

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Streptococcus pneumoniae is a Gram-positive bacterium and the leading cause of bacterial pneumonia in children and the elderly worldwide. Currently, two types of licensed vaccines are available to prevent the disease caused by this pathogen: the 23-valent pneumococcal polysaccharide-based vaccine and the 7-, 10, 13, 15 and 20-valent pneumococcal conjugate vaccine. However, these vaccines, composed of the principal capsular polysaccharide of leading serotypes of this bacterium, have some problems, such as high production costs and serotype-dependent effectiveness. These drawbacks have stimulated research initiatives into non-capsular-based vaccines in search of a universal vaccine against S. pneumoniae. In the last decades, several research groups have been developing various new vaccines against this bacterium based on recombinant proteins, live attenuated bacterium, inactivated whole-cell vaccines, and other newer platforms. Here, we review and discuss the status of non-capsular vaccines against S. pneumoniae and the future of these alternatives in a post-pandemic scenario.

show abstract

Chimeric Protein PSPF, a Potential Vaccine for Prevention Streptococcus pneumoniae Infection

Cited by 4 publications

References 32 publications

Mucosal Vaccines against Bacterial and Viral Pathogens

Mucosal Vaccines against Bacterial and Viral Pathogens

Recombinant vaccine candidates with integrated adjuvants provide stimulation of an effective immune response against bacterial infections

Non-capsular based immunization approaches to prevent Streptococcus pneumoniae infection

Contact Info

Product

Resources

About